Skip to content

Secure Checkout

Website Secured with 256-bit TLS Encryption
Subtotal: $575.00
Shipping: $10.00
$0.00
Donation Amount: $0.00
Total: $585.00
2 - 3 days
5 - 10 days

All fields are required unless marked optional.

Add Shipping Note
  • Visa
  • Mastercard
  • American Express
  • Discover
  • Paypal
  • Apple Pay
  • Google Pay

Verified and Secured. Guaranteed.

Website Secured with 256-bit TLS Encryption
Please select your payment method from the following list:
Click the button to checkout with PayPal.
You will be charged $585.00 when completing this purchase.

Cart Totals

Subtotal: $575.00
Shipping: $10.00
: $0.00
Donation Amount: $0.00
Total: $585.00

You are about to purchase:

No image available

Viscose: Direktfarbstoffe. Colorants directs. direct colours by WALTER, Richard

5 to 10 days for delivery
Standard Shipping: $10.00
Details
$575.00
( US$)
Seller: Ursus Books
Title
Viscose: Direktfarbstoffe. Colorants directs. direct colours
Author
WALTER, Richard
Seller
Ursus Books (United States)
Description
1930. WALTER, Richard. Viscose: Direktfarbstoffe. Colorants directs. Direct colours. 13 pp. text and 7 pp. containing 128 mounted fabric samples. 8vo, 245 x 167 mm, publisher's cloth. Basel: Sandoz, 1930. A handsome work on dyeing from the renowned Basel bio-chemichal company, Sandoz. As usual with these works, it is rare, with OCLC listing only one copy worldwide in Basel. Founded in 1886, like most of the famous European pharmaceutical giants, Sandoz began in the dyestuffs industry. Its original specialties were alizarian blue and auramine, a fluorescent yellow dye. Both dyes had applications in laboratories in addition to textiles dying. While it began producing pharmaceuticals after the death of its founder in 1885, Sandoz continued to be an international leader in the production of dyes and moved into global dominance with the disapearance of German dyestuffs from the market during World War I. At the time this catalogue was published, Sandoz was using the financial success from its dyes to fund its shift to the emerging markets of pharmaceuticals, but they had yet to hit on a bestseller.